Exosomes derived from stem cells in children's baby teeth successfully reversed bone loss in aged mice by reactivating mitophagy—the cellular recycling process that clears damaged mitochondria from aging bone marrow stem cells. The H2O2-treated senescent bone marrow mesenchymal stem cells regained mitochondrial function and enhanced bone-forming capacity after exosome treatment, with no organ toxicity observed. This finding represents a significant advance in regenerative medicine, offering a potentially revolutionary approach to age-related osteoporosis that affects 200 million people worldwide. Unlike current treatments that merely slow bone loss, these nano-sized vesicles appear to rejuvenate the cellular machinery responsible for bone formation at its source. The mechanism—restoring mitochondrial quality control in aging stem cells—addresses a fundamental driver of skeletal aging. However, the leap from mouse models to human application remains substantial, and the logistics of sourcing exosomes from deciduous teeth for widespread clinical use presents practical challenges. The work suggests cellular rejuvenation through mitochondrial restoration could extend beyond bone health to other age-related conditions driven by stem cell senescence.